Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 14, 2026, 9:55 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 385–408 of 489 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Esophageal Motility Disorders Clear all
Completed Phase 2 Interventional Results available

Investigate the Effect of Different Doses of Lesogaberan (AZD3355) as add-on to PPI in GERD Patients With Partial Response to PPI

NCT01005251
View directory record Official record
Conditions
Gastroesophageal Reflux Disease, Heartburn, Regurgitation
Interventions
lesogaberan (AZD3355), Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 70 Years
Enrollment
661 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Oklahoma City, Oklahoma
Source: ClinicalTrials.gov public record
Updated Apr 25, 2011 · Synced Oct 14, 2026, 9:55 PM EDT
Terminated Phase 2 Interventional Results available

Self-Propelled Versus Standard Percutaneous Endoscopic Gastrojejunostomy(PEG-J); RCT

NCT01892267
View directory record Official record
Conditions
Feeding Tube
Interventions
PEG-J placement
Device
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 80 Years
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated May 17, 2017 · Synced Oct 14, 2026, 9:55 PM EDT
Completed Phase 3 Interventional Results available

Study Evaluating the Efficacy and Safety of Pantoprazole in Infants With Symptomatic Gastroesophageal Reflux Disease (GERD)

NCT00365300
View directory record Official record
Conditions
Gastroesophageal Reflux
Interventions
pantoprazole, Placebo
Drug
Lead sponsor
Wyeth is now a wholly owned subsidiary of Pfizer
Industry
Eligibility
28 Days to 11 Months
Enrollment
129 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
38
States / cities
Mobile, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 35 more
Source: ClinicalTrials.gov public record
Updated May 4, 2010 · Synced Oct 14, 2026, 9:55 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Implementing Virtual Reality (VR) to Reduce Sedation

NCT06349564
View directory record Official record
Conditions
Sedative During Endoscopy
Interventions
Pico 4 Enterprise headset with noise cancelling headphones
Device
Lead sponsor
NYU Langone Health
Other
Eligibility
21 Years to 65 Years
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2026
U.S. locations
1
States / cities
Brooklyn, New York
Source: ClinicalTrials.gov public record
Updated Mar 19, 2026 · Synced Oct 14, 2026, 9:55 PM EDT
Completed Phase 4 Interventional

Determination of the Minimal Clinically Important Difference After Treatment With Pantoprazole in Patients With Symptoms of Acid Reflux (Gastroesophageal Reflux Disease) (BY1023/M3-340)

NCT00246909
View directory record Official record
Conditions
Gastroesophageal Reflux
Interventions
Pantoprazole
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years and older
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
51
States / cities
Alabaster, Alabama • Huntsville, Alabama • Mesa, Arizona + 43 more
Source: ClinicalTrials.gov public record
Updated May 7, 2012 · Synced Oct 14, 2026, 9:55 PM EDT
Terminated Not applicable Interventional

A Trial of Thickened Feeds to Treat Gastroesophageal Reflux in Children Admitted After Choking Spell

NCT03130543
View directory record Official record
Conditions
Apparent Life Threatening Event, Gastroesophageal Reflux, Aspiration
Interventions
Rice cereal, Enfamil AR
Dietary Supplement
Lead sponsor
Boston Children's Hospital
Other
Eligibility
0 Years to 1 Year
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 6, 2021 · Synced Oct 14, 2026, 9:55 PM EDT
Completed Phase 3 Interventional Results available

Rabeprazole Extended-Release, 50 mg, Versus Esomeprazole, 40 mg, for Healing and Symptomatic Relief of Moderate to Severe Erosive Gastroesophageal Reflux Disease (GERD)

NCT00658775
View directory record Official record
Conditions
Gastroesophageal Reflux Disease (GERD)
Interventions
Rabeprazole sodium, Esomeprazole
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
1,069 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Moline, Illinois
Source: ClinicalTrials.gov public record
Updated Dec 21, 2015 · Synced Oct 14, 2026, 9:55 PM EDT
Completed Phase 2 Interventional

An Efficacy and Safety Study of XP19986 in Subjects With Symptomatic GERD

NCT00557401
View directory record Official record
Conditions
Gastroesophageal Reflux
Interventions
XP19986 SR3, 20 mg QD, XP19986 SR3, 40 mg QD, XP19986 SR3, 60 mg QD, XP19986 SR3, 30 mg BID, Placebo
Drug
Lead sponsor
XenoPort, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
156 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
Irvine, California
Source: ClinicalTrials.gov public record
Updated Feb 21, 2021 · Synced Oct 14, 2026, 9:55 PM EDT
Completed Not applicable Interventional

Clinical Trial Comparing Open and Laparoscopic Nissen Fundoplication in Children

NCT00382850
View directory record Official record
Conditions
Gastroesophageal Reflux
Interventions
Nissen fundoplication
Procedure
Lead sponsor
Johns Hopkins University
Other
Eligibility
Up to 24 Months
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2010
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 1, 2018 · Synced Oct 14, 2026, 9:55 PM EDT
Completed Phase 1 Interventional Results available

Pharmacokinetic and Safety of Dexlansoprazole in Adolescents With Gastroesophageal Reflux Disease

NCT00847210
View directory record Official record
Conditions
Gastroesophageal Reflux
Interventions
Dexlansoprazole MR
Drug
Lead sponsor
Takeda
Industry
Eligibility
12 Years to 17 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
3
States / cities
Anaheim, California • Cypress, California • Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Feb 2, 2012 · Synced Oct 14, 2026, 9:55 PM EDT
Completed Phase 4 Interventional

Esomeprazole for Treatment of GERD in Pediatric Patients

NCT00228527
View directory record Official record
Conditions
Gastroesophageal Reflux Disease (GERD), Erosive Esophagitis, Non-erosive Esophagitis
Interventions
Esomeprazole (Nexium)
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
1 Year to 11 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
24
States / cities
Mobile, Alabama • Phoenix, Arizona • Wilmington, Delaware + 21 more
Source: ClinicalTrials.gov public record
Updated Nov 19, 2010 · Synced Oct 14, 2026, 9:55 PM EDT
Completed Not applicable Interventional Results available

Response to Supplement and Placebo in GERD

NCT01915173
View directory record Official record
Conditions
Gastroesophageal Reflux Disease (GERD), Heartburn, Dyspepsia
Interventions
Supplement, Placebo, Expanded Interview, Standard Interview
Drug · Behavioral
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years to 80 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 29, 2017 · Synced Oct 14, 2026, 9:55 PM EDT
Withdrawn Not applicable Interventional

HLT® Meridian® TAVR Valve System Early Feasibility Study for Aortic Regurgitation

NCT05409378
View directory record Official record
Conditions
Aortic Regurgitation
Interventions
The HLT® Meridian® TAVR Valve (Meridian® with TriVentTM Anticalcification Treatment Valve and Pathfinder® Delivery System)
Device
Lead sponsor
HLT Inc.
Industry
Eligibility
Not listed
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
3
States / cities
Chicago, Illinois • Cincinnati, Ohio • Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated May 31, 2023 · Synced Oct 14, 2026, 9:55 PM EDT
Completed No phase listed Observational

Quality of Life After Esophagectomy for Cancer

NCT00798746
View directory record Official record
Conditions
Esophageal Cancer
Interventions
Telephone Questionnaire
Behavioral
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
88 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 31, 2012 · Synced Oct 14, 2026, 9:55 PM EDT
Completed No phase listed Observational

Biology in Patients With Reflux Esophagitis

NCT01194323
View directory record Official record
Conditions
GERD
Interventions
Not listed
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Apr 4, 2017 · Synced Oct 14, 2026, 9:55 PM EDT
Completed Phase 3 Interventional Results available

Phase 3/Safety & Efficacy of Esomeprazole in Infants

NCT00468559
View directory record Official record
Conditions
Gastroesophageal Reflux Disease (GERD)
Interventions
Open Label Run In Esomeprazole, Double Blind Esomeprazole, Double Blind Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
1 Month to 11 Months
Enrollment
98 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
14
States / cities
Phoenix, Arizona • Atlanta, Georgia • Park Ridge, Illinois + 11 more
Source: ClinicalTrials.gov public record
Updated Jun 2, 2014 · Synced Oct 14, 2026, 9:55 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

A Randomized Trial of Medical and Surgical Treatments for Patients With GERD Symptoms That Are Refractory to Proton Pump Inhibitors

NCT01265550
View directory record Official record
Conditions
GERD
Interventions
Nissen fundoplication, baclofen, Desipramine
Device · Drug
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years to 64 Years
Enrollment
366 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2016
U.S. locations
15
States / cities
Birmingham, Alabama • Tucson, Arizona • Loma Linda, California + 12 more
Source: ClinicalTrials.gov public record
Updated Jan 22, 2020 · Synced Oct 14, 2026, 9:55 PM EDT
Completed Not applicable Interventional

Per Oral Endoscopic Myotomy (POEM) for Esophagogastric Junction Outflow Obstruction (EGOO)

NCT01942018
View directory record Official record
Conditions
Esophagogastric Junction Outflow Obstruction
Interventions
POEM
Procedure
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 70 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated May 28, 2020 · Synced Oct 14, 2026, 9:55 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Effect of Obesity on Proton Pump Inhibitors

NCT04248335
View directory record Official record
Conditions
Pediatric Obesity, NAFLD, GERD
Interventions
Lansoprazole, Pantoprazole, Midazolam
Drug
Lead sponsor
Children's Mercy Hospital Kansas City
Other
Eligibility
6 Years to 21 Years
Enrollment
76 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2024
U.S. locations
1
States / cities
Kansas City, Missouri
Source: ClinicalTrials.gov public record
Updated Jun 4, 2026 · Synced Oct 14, 2026, 9:55 PM EDT
Not listed Phase 3 Interventional

Effect of Rozerem on the Perception of GERD Symptoms in Patients With Chronic Insomnia.

NCT01128582
View directory record Official record
Conditions
Gastroesophageal Reflux Disease, Chronic Insomnia
Interventions
Rozerem (ramelteon), placebo
Drug
Lead sponsor
Southern Arizona VA Health Care System
Federal
Eligibility
Up to 82 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Tucson, Arizona
Source: ClinicalTrials.gov public record
Updated May 12, 2011 · Synced Oct 14, 2026, 9:55 PM EDT
Completed Not applicable Interventional

The Role of HIF-2a in the Pathogenesis of Reflux Esophagitis

NCT01733810
View directory record Official record
Conditions
Esophagitis, Reflux Esophagitis, Gastroesophageal Reflux Disease
Interventions
Cessation of Acid Suppressing Medications
Other
Lead sponsor
Dallas VA Medical Center
Federal
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Feb 5, 2020 · Synced Oct 14, 2026, 9:55 PM EDT
Completed Phase 2 Interventional Results available

Treatment of Gastroesophageal Reflux Disease in 12-16 Year Old Patients With Rabeprazole

NCT00132496
View directory record Official record
Conditions
Gastroesophageal Reflux Disease
Interventions
rabeprazole sodium
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
12 Years to 16 Years
Enrollment
111 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
25
States / cities
Longmont, Colorado • Fort Lauderdale, Florida • New Port Richey, Florida + 21 more
Source: ClinicalTrials.gov public record
Updated Dec 3, 2009 · Synced Oct 14, 2026, 9:55 PM EDT
Completed Phase 3 Interventional

Endoscopic Evidence of Maintenance of Healing With Oral NEXIUM in Patients 1 to 11 Years Old With Erosive Esophagitis.

NCT05267613
View directory record Official record
Conditions
Erosive Esophagitis
Interventions
Nexium 20mg, Nexium 10mg
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
1 Year to 11 Years
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
11
States / cities
Mobile, Alabama • Sacramento, California • Miami, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Oct 14, 2026, 9:55 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Correlation of Oropharyngeal Pepsin and Gastroesophageal (GE) Reflux

NCT01091805
View directory record Official record
Conditions
Gastroesophageal Reflux Disease (GERD)
Interventions
Not listed
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
Not listed
Enrollment
143 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2013
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 13, 2017 · Synced Oct 14, 2026, 9:55 PM EDT